To Demonstrate the Relative Bioavailability of Geneva and Dista (Prozac) 20 mg Fluoxetine Hydrochloride Capsules (Pulvules) In Healthy Adult Males Under Fasting Conditions
Primary Purpose
Depression
Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Fluoxetine Hydrochloride 20 mg Capsules (Geneva Pharmaceutical, Inc.)
Prozac Fluoxetine Hydrochloride 20 mg Capsules (Dista)
Sponsored by

About this trial
This is an interventional treatment trial for Depression
Eligibility Criteria
Inclusion Criteria:
- No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.
Exclusion Criteria:
- Positive test results for HIV or hepatitis B or C.
- Treatment for drug or alcohol dependence.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
1
2
Arm Description
Fluoxetine Hydrochloride 20 mg Capsules (Geneva Pharmaceutical, Inc.)
Prozac Fluoxetine Hydrochloride 20 mg Capsules (Dista)
Outcomes
Primary Outcome Measures
Bioequivalence based on AUC and Cmax
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00913718
Brief Title
To Demonstrate the Relative Bioavailability of Geneva and Dista (Prozac) 20 mg Fluoxetine Hydrochloride Capsules (Pulvules) In Healthy Adult Males Under Fasting Conditions
Official Title
Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Geneva and Dista (Prozac) 20 mg Fluoxetine Hydrochloride Capsules (Pulvules) In Health Adult Males Under Fasting Conditions Following Administration of a 40 mg Dose
Study Type
Interventional
2. Study Status
Record Verification Date
June 2009
Overall Recruitment Status
Completed
Study Start Date
June 1996 (undefined)
Primary Completion Date
July 1996 (Actual)
Study Completion Date
July 1996 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Sandoz
4. Oversight
5. Study Description
Brief Summary
To demonstrate the relative bioavailability of Geneva and Dista (Prozac) 20 mg Fluoxetine Hydrochloride capsules (Pulvules) in healthy adult males under fasting conditions.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Depression
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
46 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Arm Description
Fluoxetine Hydrochloride 20 mg Capsules (Geneva Pharmaceutical, Inc.)
Arm Title
2
Arm Type
Active Comparator
Arm Description
Prozac Fluoxetine Hydrochloride 20 mg Capsules (Dista)
Intervention Type
Drug
Intervention Name(s)
Fluoxetine Hydrochloride 20 mg Capsules (Geneva Pharmaceutical, Inc.)
Intervention Type
Drug
Intervention Name(s)
Prozac Fluoxetine Hydrochloride 20 mg Capsules (Dista)
Primary Outcome Measure Information:
Title
Bioequivalence based on AUC and Cmax
Time Frame
86 days
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.
Exclusion Criteria:
Positive test results for HIV or hepatitis B or C.
Treatment for drug or alcohol dependence.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Roderick Malone, M.D.
Organizational Affiliation
Clinical Research Center (Cincinnati)
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
To Demonstrate the Relative Bioavailability of Geneva and Dista (Prozac) 20 mg Fluoxetine Hydrochloride Capsules (Pulvules) In Healthy Adult Males Under Fasting Conditions
We'll reach out to this number within 24 hrs